Back
Halozyme Therapeutics 10K Form
Buy
53
HALO
Halozyme Therapeutics
Last Price:
47.79
Seasonality Move:
17.34%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-07 | 10Q | HALO/Halozyme Therapeutics Quarterly |
| 2023-11-06 | 10Q | HALO/Halozyme Therapeutics Quarterly |
| 2023-08-08 | 10Q | HALO/Halozyme Therapeutics Quarterly |
| 2023-05-09 | 10Q | HALO/Halozyme Therapeutics Quarterly |
| 2022-11-08 | 10Q | HALO/Halozyme Therapeutics Quarterly |
| 2022-08-09 | 10Q | HALO/Halozyme Therapeutics Quarterly |
Receive HALO News And Ratings
See the #1 stock for the next 7 days that we like better than HALO
HALO Financial Statistics
Sales & Book Value
| Annual Sales: | $829.25M |
|---|---|
| Cash Flow: | $113.86M |
| Price / Cash Flow: | 15.8 |
| Annual Sales: | $3.56 |
| Price / Book: | 13.43 |
Profitability
| EPS (TTM): | 3.02000 |
|---|---|
| Net Income (TTM): | $392.47M |
| Gross Margin: | $636.89M |
| Return on Equity: | 156.62% |
| Return on Assets: | 20.54% |
Halozyme Therapeutics Earnings Forecast
Key Halozyme Therapeutics Financial Ratios
- The Gross Profit Margin over the past 23 years for HALO is 76.80%.
- The Selling, General & Administrative Expenses for HALO have been equal to 17.99% of Gross Profit Margin.
- The Research & Development expenses have been 9.21% of Revenue.
- The Interest Expense is 6.66% of Operating Income.
- The Net Earning history of HALO is 33.96% of Total Revenues.
- Per Share Earnings over the last 23 years have been positive in 11 years.
Halozyme Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | HALO |
| CUSIP: | 40637H |
| Website: | halozyme.com |
Debt
| Debt-to-Equity Ratio: | 3.32 |
|---|---|
| Current Ratio: | 10.36 |
| Quick Ratio: | 8.75 |
Price-to-Earnings
| Trailing P/E Ratio: | 22.76 |
|---|---|
| Forward P/E Ratio: | 10.2 |
HALO Technical Analysis vs Fundamental Analysis
Buy
53
Halozyme Therapeutics (HALO)
is a Buy
Is Halozyme Therapeutics a Buy or a Sell?
-
Halozyme Therapeutics stock is rated a Buy
The current Halozyme Therapeutics [HALO] share price is $47.79. The Score for HALO is 53, which is 6% above its historic median score of 50, and infers lower risk than normal.